Overview

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The overall objective of this proposal is to execute a real-world database analysis to evaluate hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients in the U.S.

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Apixaban
Dabigatran
Rivaroxaban
Warfarin